Company Facts & Figures

At Teva, we are all in for better health.

01

Enabling access to quality medicines and treatment options

3,600
medicines
37,000
employees
200,000,000
people served every day

Teva offers the world’s largest medicine cabinet - a full spectrum of products from generics, API and over-the-counter products to specialty and biologic treatments.

Teva was established in 1901. Our global headquarters are based in Israel. Today we have a portfolio of more than 3,600 medicines, and produce approximately 76 billion tablets and capsules a year. We have over 53 manufacturing facilities in more than 33 countries. 01 

We rank among the leading pharmaceutical companies in the world and are active in 60 markets. Approximately 37,000 employees around the world are dedicated to our mission. Our innovative and high quality medicines serve about 200 million people every day. 02

02

Focused on developing innovative medicines in core therapeutic areas

Movement disorders and neuro-degeneration

Migraine

Neuropsychiatry

Respiratory

03

Global generic leadership

$
Billion
43
Annual savings to healthcare systems
in 14 of our markets in 2020

Top 3 leadership position in over 25 markets

1 in 12
prescriptions in the US
1 in 8
prescriptions in Germany
1 in 5
prescriptions in the UK
04

Strong operational base, global infrastructure and scale

53
production sites
76
billion Tablets & Capsules annually
05

A fully integrated R&D function

27
research & development sites worldwide
~200
clinical & pharmacokinetic studies conducted annually for Teva generics, biosimilars & innovative medicines
~33K
licenses for Teva medicines maintained by Global Regulatory Affairs annually
06

Global reach

60
commercial markets
3,600
different products in our global portfolio

Notes and References

  1. Back to contents.

    Data source for number of products & facilities: Teva Global Operations

  2. Back to contents.

    Internal analyses conducted by Global Insights, Access & Technologies estimating number of Teva consumers. Ref 2.1 dated August 2016; Ref 2.2 dated April 2019

Data confirmed as of March 2023